Cardiologists' and nephrologists' management of atrial fibrillation in hemodialysis patients
.

BACKGROUND: Antithrombotic therapy for stroke prevention in atrial fibrillation (AF) is considered a standard of care, but for hemodialysis (HD) patients the benefits are unclear, and bleeding risks are high. Our study objective was to compare cardiologists' and nephrologists' stroke prevention practices in different patient risk scenarios. MATERIALS AND METHODS: A cross-sectional, online survey was distributed to members of three Canadian physician societies (Nephrology, Cardiovascular, Heart Rhythm), and to cardiologists affiliated with three Canadian Universities. The questionnaire included four AF scenarios in HD patients with varying stroke and bleeding risks. Physicians selected one of six antithrombotic therapy options for each scenario. RESULTS: Cardiologists were 3 times more likely than nephro-logists to choose anticoagulant therapy over both antiplatelet and no drug therapy, regardless of stroke or bleeding risk (p < 0.001). Physicians' drug therapy choices in regards to level of stroke and bleeding risk reflected the expected pattern based on current evidence. CONCLUSION: Cardiologists were more likely to prescribe anticoagulant therapy for AF in the HD population compared to nephrologists, regardless of patient stroke or bleeding risk.

Audit of community pharmacists' prescribing interventions: Quality assessment of a newly reimbursed service.

OBJECTIVES: To evaluate community pharmacists' reimbursed prescribing interventions (called pharmaceutical opinions/POs in Canada) by determining the types of drug-related problems (DRPs) identified; the type, quality, and clinical impact of recommendations made; and variation in recommendation quality across regions, pharmacy ownership type, and pharmacy size. DESIGN: Retrospective audit of randomly sampled service documentation records. SETTING: Community pharmacies in Ontario, Canada, 3 years after implementation of a government program that reimburses pharmacies for providing DRP-based POs to physicians. PARTICIPANTS: Thirty-six community pharmacies in 4 regions of Ontario. MAIN OUTCOME MEASURES: For each PO, 2 experienced clinical pharmacists independently, and then by consensus, determined the primary drug implicated and its therapeutic category, the type of DRP, and the type of prescriber recommendation. Each PO recommendation was assessed for clinical impact, evidence base, and overall quality. Chi-square analyses assessed the relationship between PO quality and pharmacy characteristics. RESULTS: Of 563 POs, 261 (46%) met reimbursement criteria for stating a DRP and prescriber recommendation. Among these eligible POs, systemic antiinfective (22%), alimentary tract and metabolism (19%), nervous system (15%), and cardiovascular (15%) drugs were most commonly identified in the DRP. Adverse drug reactions (which included drug interactions) were the most common type of DRP (42.5%), followed by "dose too high" (16%) and "needs additional therapy" (14%). Top recommendations were to change the drug (41%) and to decrease the dose (20%). The quality of the pharmacist's recommendation was judged to be good to excellent in 70% of the 261 eligible POs; quality was associated with region and ownership type. CONCLUSION: PO quality was suboptimal: the primary issue was failure to state a prescriber recommendation. Collaborative efforts are needed from community pharmacy stakeholders (schools of pharmacy, regulatory colleges, and continuing education providers) to help pharmacists enhance the quality of their POs, beginning with their clinical documentation skills.

Multiple mini-interview predictive validity for performance on a pharmacy licensing examination.

CONTEXT: Predictive validity studies on the use of the multiple mini-interview (MMI) have been primarily in medicine. OBJECTIVES: This study sought to determine the predictive validity of the MMI for performance within a pharmacy programme and on the Pharmacy Examining Board of Canada (PEBC) Qualifying Examination for licensure, and to compare the predictive validity of the MMI with that of pre-pharmacy grade point average (GPA) and Pharmacy College Admission Test (PCAT) score. METHODS: Admissions data for 223 graduates of the pharmacy programme at the University of Toronto were matched to programme and licensure outcome measures. Multiple linear regression assessed the predictive ability of the MMI, pre-pharmacy GPA, PCAT and covariates for performance in final-year experiential rotations, cumulative GPA (cGPA) and PEBC-MCQ (multiple-choice question examination) and PEBC-OSCE (objective structured clinical examination) overall and subcomponent scores. RESULTS: The PCAT, pre-pharmacy GPA and age significantly predicted the PEBC-MCQ overall score. The MMI was the only significant predictor of overall score on the PEBC-OSCE (ß = 0.17, p = 0.02); it also predicted communication and performance subscores. Scores on the PCAT and female gender predicted the communication subscore. Pre-pharmacy GPA, age and female gender significantly predicted cGPA. The MMI was the only significant predictor of institutional/ambulatory rotation score (ß = 0.26, p = 0.00). CONCLUSIONS: The MMI, designed to measure non-academic attributes including communication, motivation and problem-solving skills, was the only admissions tool with significant predictive validity for performance on the PEBC-OSCE national pharmacy certification examination and in an institutional/ambulatory rotation. These findings, from a single cohort of undergraduates, provide the first report of the predictive validity of the MMI for performance on pharmacy licensure examinations and thereby strengthen the evidence for its use in health professions selection. Prior university academic performance significantly predicted cGPA and performance on the PEBC-MCQ. Performance on the PCAT also predicted PEBC-MCQ results.

Factors affecting the delivery of community pharmacist-led medication reviews: evidence from the MedsCheck annual service in Ontario.

BACKGROUND: Medication reviews have become part of pharmacy practice across developed countries. This study aimed to identify factors affecting the likelihood of eligible Ontario seniors receiving a pharmacy-led medication review called MedsCheck annual (MCA). METHODS: We designed a cohort study using a random sample of pharmacy claims for MCA-eligible Ontario seniors using linked administrative data from April 2012 to March 2013. Guided by a conceptual framework, we constructed a generalized-estimating-equations model to estimate the effect of patient, pharmacy and community factors on the likelihood of receiving MCA. RESULTS: Of the 2,878,958 eligible claim-dates, 65,605 included an MCA. Compared to eligible individuals who did not receive an MCA, recipients were more likely to have a prior MCA (OR = 3.03), receive a new medication on the claim-date (OR = 1.78), be hypertensive (OR = 1.18) or have a recent hospitalization (OR = 1.07). MCA recipients had fewer medications (e.g., OR = 0.44 for ≥12 medications versus 0-4 medications), and were less likely to receive an MCA in a rural (OR = 0.74) or high-volume pharmacy (OR = 0.65). CONCLUSIONS: The most important determinant of receiving an MCA was having had a prior MCA. Overall, MCA recipients were healthier, younger, urban-dwelling, and taking fewer medications than non-recipients. Policies regarding current and future medication review programs may need to evolve to ensure that those at greatest need receive timely and comprehensive medication reviews.

Uptake of the MedsCheck annual medication review service in Ontario community pharmacies between 2007 and 2013.

BACKGROUND: MedsCheck Annual (MCA) is an Ontario government-funded medication review service for individuals taking 3 or more prescription medications for chronic conditions. METHODS: This cohort study analyzed linked administrative claims data from April 1, 2007, to March 31, 2013. Trends in MCA claims and recipient characteristics were examined. RESULTS: A total of 1,498,440 Ontarians (55% seniors, 55% female) received an MCA. One-third (36%) had 2 or more MCAs within 6 years. Service provision increased over time, with a sharper increase from 2010 onward. Almost half of Ontario pharmacies made at least 1 MCA claim in the first month of the program. Hypertension, respiratory disease, diabetes, psychiatric conditions and arthritis were common comorbidities. Recipients older than 65 years were most commonly dispensed an antihypertensive and/or antihyperlipidemic drug in the prior year and received an average of 11 unique prescription medications. Thirty-eight percent of recipients visited an emergency department or were hospitalized in the year prior to their first MCA. DISCUSSION: Over the first 6 years of the program, approximately 1 in 9 Ontarians received an MCA. There was rapid and widespread uptake of the service. Common chronic conditions were well represented among MCA recipients. Older MCA recipients had less emergency department use compared with population-based estimates. CONCLUSIONS: Medication reviews increased over time; however, the number of persons receiving the service more than once was low. Service delivery was generally consistent with program eligibility; however, there are some findings possibly consistent with delivery to less complex patients.

Exploring deprescribing opportunities for community pharmacists using the Behaviour Change Wheel.

BACKGROUND: Deprescribing, the planned and supervised process of stopping or reducing doses of medications, can reduce the use of harmful or unnecessary medications. However, deprescribing is challenging for patients and prescribers to implement. Community pharmacists have the potential to contribute to deprescribing, but whether they are well positioned to do so effectively remains unclear. OBJECTIVES: To explore community pharmacists' involvement with deprescribing, and identify strategies for enhancing this involvement. METHODS: We conducted qualitative telephone interviews with 17 community pharmacists in Ontario, Canada. The Behaviour Change Wheel's COM-B model was used to inform the development of the interview guide. Four investigators coded three transcripts independently to develop the codebook. One investigator coded the remainder and generated themes relating to the first study objective using inductive thematic analysis. Two phases of analysis were then used to satisfy the second study objective: the first without the explicit use of theory, and the second using the Behaviour Change Wheel as a theoretical framework. RESULTS: Pharmacists' involvement in deprescribing was affected by: 1) their understanding of which medications should be stopped and by whom, 2) their access to patient information, and 3) competing clinical and business/technical demands of their daily activities. Findings support recommendations for optimizing community pharmacists' involvement in deprescribing by focusing on specific steps within deprescribing, expanding pharmacists' understanding of how to integrate deprescribing into their practices, and defining their deprescribing role with multi-stakeholder engagement. CONCLUSIONS: This study is the first to connect community pharmacists' real-world deprescribing challenges with theory-informed recommendations for enhancing their contributions to deprescribing. This study also explored the role of theory in pragmatically-oriented qualitative work by analyzing data without the explicit use of theory as the first step to analysis. Findings inform recommendations for enhancing community pharmacists' contributions to deprescribing.

Exploring pharmacy service users' support for and willingness to use community pharmacist prescribing services.

BACKGROUND: In 2012, community pharmacists in Ontario, Canada gained regulatory authority to independently prescribe, including renew and adapt prescriptions. Studies have explored views of pharmacists, physicians and policymakers about pharmacist prescribing but less is known about the views of community pharmacy services users. OBJECTIVE: To describe Ontario community pharmacy service users' support for and stated willingness to use pharmacist prescribing services. METHODS: A qualitative descriptive study was conducted with 19 adults who had filled or refilled prescription(s) at a community pharmacy within the past three months. Participants were recruited through purposive and snowball sampling. Data were collected through one-on-one, semi-structured interviews between May and September 2016. Interview transcripts were coded and thematic analysis conducted. The first two transcripts were independently coded and analyzed by 2 researchers and after consensus was achieved, the lead researcher coded and analyzed the remainder of the data. RESULTS: Most community pharmacy service users lacked experience with pharmacist prescribing services but perceived some potential benefits, including personal convenience. The majority of participants supported pharmacist prescribing. Support for and stated willingness to use pharmacist prescribing services varied by the type of service and was contingent upon the clinical purpose of the prescription, pharmacists' access to patient clinical information (e.g. health records), and the extent of pharmacist-physician collaboration during the prescribing process. CONCLUSION: Community pharmacy service users in Ontario expressed varying support for and stated willingness to use pharmacist prescribing services. This seemed to be due to their perceptions of the pharmacists' role (compared to physicians) and concerns about risks. Understanding these contributing factors will help implement strategies that address concerns and facilitate use of community pharmacists' prescribing services.

Home Care Pharmacy Practice in Canada: A Cross-Sectional Survey of Services Provided, Remuneration, Barriers, and Facilitators.

BACKGROUND: As the population ages, and individuals desire to remain in their homes as long as possible, the need for in-home care is expected to increase. However, pharmacists have rarely been included in studies of in-home care, and little is known about the prevalence or effectiveness of pharmacists' home-based services in Canada. OBJECTIVE: To identify pharmacy practices in Canada that regularly provide in-home patient care and to identify specific services provided, remuneration obtained, and barriers and facilitators influencing the provision of home-based care. METHODS: A link to a web-based survey was posted in e-newsletters of provincial, territorial, and national pharmacy associations in Canada. In addition, pharmacists known to the researchers as providing in-home clinical services were contacted directly. The survey was open from October to December 2015. Practices or organizations that performed at least one home visit per week for clinical purposes, with documentation of the services provided, were eligible to participate. One response per practice or organization was allowed. RESULTS: Seventeen practices meeting the inclusion criteria were identified, representing community, hospital, and clinic settings. Home visits were most commonly performed for individuals with complex medication regimens or nonadherence to medication therapy. The most common services were conducting medication reconciliation and reviews and counselling patients about medication adherence. No practices or organizations billed patients for these services, yet lack of remuneration was an important barrier identified by many respondents. Although 12 (71%) of the respondents collected data for evaluative purposes, collection of clinical or health system outcome data was rare. CONCLUSIONS: Few Canadian pharmacy practices that provide in-home patient care at least once a week could be identified. Data collection suitable to establish an evidence base for this service was infrequently performed by practices and organizations providing home-based care. Such evidence is needed to justify the expansion of this service nationally, including consistent and adequate remuneration from governments or other payers.

CONTEXTE: Au fur et à mesure que la population vieillit et que les gens désirent rester le plus longtemps possible à leur domicile, on s'attend à une croissance des besoins de soins à domicile. Or, les pharmaciens ont rarement été inclus dans les études de soins à domicile et l'on connaît peu de choses sur la prévalence et l'efficacité des services de soins à domiciles prodigués par des pharmaciens au Canada. OBJECTIFS: Recenser les pharmacies au Canada qui prodiguent régulièrement des soins à domicile et déterminer précisément quels sont les services fournis, la rémunération obtenue et les éléments qui font obstacle ou facilitent la prestation de soins à domicile. MÉTHODES: Un lien menant à un sondage en ligne a été inclus dans les infolettres d'associations provinciales, territoriales et nationales de pharmacie au Canada. De plus, les chercheurs ont communiqué directement avec les pharmaciens dont ils savaient qu'ils offraient des services cliniques à domicile. Le sondage était accessible d'octobre à décembre 2015. Les pharmacies ou les organismes qui faisaient au moins une visite à domicile par semaine à des fins cliniques et qui consignaient les services fournis étaient admissibles à l'étude. Une réponse par pharmacie ou par organisme était permise. RÉSULTATS: Dix-sept pharmacies répondant aux critères d'inclusion ont été recensées. Elles provenaient de milieux communautaire, hospitalier et clinique. Les visites à domicile étaient le plus souvent faites auprès de personnes ayant une pharmacothérapie complexe ou n'observant pas le traitement médicamenteux. Les services les plus fréquents étaient : établir des bilans comparatifs des médicaments, procéder à des évaluations de la pharmacothérapie et offrir de l'information aux patients sur l'observance pharmacothérapeutique. Aucune pharmacie ou aucun organisme n'a facturé ces services aux patients; or, l'absence de rémunération représentait un des principaux obstacles selon bon nombre de répondants. Bien que 12 (71 %) des répondants aient recueilli des données à des fins d'évaluation, on effectuait rarement la cueillette de données sur les résultats cliniques ou du système de santé. CONCLUSIONS: On a pu recenser que peu de pharmacies canadiennes qui offrent des soins à domicile aux patients au moins une fois par semaine. On a noté qu'on réalisait trop peu fréquemment la collecte de données permettant de fournir un fondement à ce service. De telles données probantes sont nécessaires pour justifier le fait d'étendre ce service à l'ensemble du pays et de dégager une rémunération uniforme et adéquate provenant des gouvernements ou d'autres payeurs.

Uptake of Community Pharmacist-Delivered MedsCheck Diabetes Medication Review Service in Ontario between 2010 and 2014.

OBJECTIVES: The objective of the study was to describe the demographic and clinical characteristics of MedsCheck Diabetes (MCD) recipients in Ontario between program launch on September 1, 2010, and March 31, 2014. METHODS: This cohort study leveraged linked administrative claims data. Trends in MCD claims and recipient characteristics were examined. RESULTS: A total of 406,694 Ontarians (45.8% women) received an MCD, representing approximately half of all Ontarians with diabetes. Recipients were more likely to be <66 years of age (54.6%), live in an urban centre (94.6%) and be native to Canada (81.0%). A total of 13,587 MCD follow ups were completed (4.1% of MCD recipients ≥66 years of age and 2.7% of MCD recipients <66 years of age). MCD recipients ≥66 years of age had received a mean of 11 unique prescription medications in the previous year, prior to receiving an MCD, and 12.9% had had high medication costs ($4000+) in the previous year. Metformin was dispensed to 76.4% of recipients, insulin to 20.1% and insulin secretagogues to 36.2%. The most common medication classes used by MCD recipients, other than antihyperglycemics, were antihypertensives (89.5%), antilipid therapies (83.8%), diuretics (52.1%), antibiotics (38.2%) and gastroprotective agents (34.9%). They were also taking high-risk medications, including narcotics (25.4%), anticoagulants (23.3%), nonsteroidal anti-inflammatory drugs (NSAIDs) (21.5%), benzodiazepines (15.5%) and glyburide (15.8%). CONCLUSIONS: Over the first 3.5 years of the program, approximately half of Ontarians with diabetes received an MCD. Follow-up assessments were low (2.7% to 4.1% of the population). Ongoing evaluation of the program is required to ensure that continuity of care is being provided to this population.

Implementation of a reimbursed medication review program: Corporate and pharmacy level strategies.

BACKGROUND: In 2006, the Ontario drug plan greatly reduced community pharmacy reimbursement for generic drugs. In exchange, a fee-for-service medication review program was introduced to help patients better understand their medication therapy and ensure that medications were taken as prescribed. A qualitative study of community pharmacy implementation strategies was undertaken to inform a mixed methods evaluation of the program. PURPOSE: To describe strategies used by community pharmacies to implement a government-funded medication review service. METHODS: Key informant interviews were conducted with pharmacy corporate executives and managers, as well as independent pharmacy owners. All pharmacy corporations in the province were approached; owners were purposively sampled from the registry of the pharmacist licensing body to obtain diversity in pharmacy attributes; and pharmacy managers were identified through a mix of snowball and registry sampling. Thematic qualitative coding and analysis were applied to interview transcripts. RESULTS: 42 key informants, including 14 executives, 15 managers/franchisees, and 11 owners, participated. The most common implementation strategy was software adaptation to flag eligible patients and to document the service. Human resource management (task shifting to technicians and increasing the technician complement), staff training, and patient identification and recruitment processes were widely mentioned. Motivational strategies including service targets and financial incentives were less frequent but controversial. Strategies typically unfolded over time, and became multifaceted. Apart from the use of targets in chain pharmacies only, strategies were similar across pharmacy ownership types. DISCUSSION: Ontario community pharmacies appeared to have done little preplanning of implementation strategies. Strategies focused on service efficiency and quantity, rather than quality. Unlike other jurisdictions, many managers supported the use of targets as motivators, and very few reported feeling pressured. This detailed account of a range of implementation strategies may be of practical value to community pharmacy decision makers.

Development and validation of the pediatric nausea assessment tool for use in children receiving antineoplastic agents.

STUDY OBJECTIVE: To develop and validate an instrument to assess nausea intensity in children aged 4-18 years. DESIGN: Prospective, descriptive study. SETTING: Tertiary-quaternary, university-affiliated pediatric hospital. PATIENTS: Four pediatric inpatient groups (177 patients): group 1 (107), those receiving cancer chemotherapy; group 2 (24), those receiving cancer chemotherapy before hematopoietic stem cell transplantation; group 3 (23), those with cancer who were not receiving cancer chemotherapy; and group 4 (23), those without cancer. INTERVENTION: We developed a scale with a standard script for administration, the Pediatric Nausea Assessment Tool (PeNAT). Revisions were made after face validity testing with clinicians and parents, and pilot testing with 15 inpatients undergoing chemotherapy. MEASUREMENTS AND MAIN RESULTS: The PeNAT scores were obtained 4-24 hours after chemotherapy in groups 1 and 2. Dietary intake scores and number of emetic episodes were recorded for the 4 hours before PeNAT administration for all patients in group 2 and 36 patients in group 1. Parents of a subset of patients made an independent assessment of their child's nausea and pain intensities immediately before PeNAT administration. Reliability was evaluated in groups 1 and 2 by correlating the first and second (obtained 1 hr after the first) PeNAT scores. Construct validity was evaluated by comparing PeNAT scores in groups 1-4. Criterion-related validity was evaluated by correlating PeNAT scores with emetic episodes and dietary intake. Convergent and discriminant validity were evaluated by correlating PeNAT scores with parental assessments of nausea and pain. Significant differences in PeNAT scores were noted among the study groups (p=0.035). Moderate correlation was noted between the first and second PeNAT scores (Spearman rho = 0.649). The PeNAT scores correlated modestly with emetic episodes (Spearman rho = 0.322) but not with dietary intake (Spearman rho = -0.217). Children's PeNAT scores correlated moderately with their parents' assessment of nausea (Spearman rho = 0.442), whereas little correlation was seen between children's PeNAT scores and parents' assessment of pain (Spearman rho = 0.167). CONCLUSION: The PeNAT is a new instrument that can be used by children to assess nausea intensity.

Willingness to pay for inhaled insulin: a contingent valuation approach.

PURPOSE: To determine the willingness to pay (WTP) of patients with diabetes mellitus for inhaled insulin. METHODS: A contingent valuation survey was administered to 96 diabetic outpatients at St. Michael's Hospital, Toronto, Canada. Standardised information about inhaled insulin and subcutaneous rapid-acting insulin was provided via video. Participants' WTP for their preferred product was elicited in Canadian dollars (Can dollars) using a 'payment-scale' method. RESULTS: The mean age of participants was 51.8 years (SD 13.4). Seventy-seven patients had type 2 and 19 had type 1 diabetes. Significantly more participants preferred inhaled insulin over subcutaneous insulin (85 vs 11; p < 0.01). Mean monthly WTP for inhaled insulin (153.70 Can dollars, SD 99.90) was significantly more than the typical 50 Can dollars per month for subcutaneous insulin (p < 0.01). Significantly more participants with type 2 diabetes using oral drugs than those with type 1 diabetes and using insulin preferred inhaled insulin (98.5% vs 69%, p < 0.001). Diabetic patients who did not use insulin were willing to pay significantly more than were insulin users (p < 0.001). Multiple regression analysis showed that income was significantly associated with WTP for inhaled insulin. CONCLUSION: Diabetic patients, particularly those who are not using insulin, indicated that they would prefer inhaled insulin over insulin injection and would be willing to pay a substantial amount per month to use it. An economic evaluation of inhaled insulin would provide important information to healthcare policy decision makers and private payers about its economic value.

Relationship between daily dose frequency and adherence to antihypertensive pharmacotherapy: evidence from a meta-analysis.

BACKGROUND: Rates of patient adherence (compliance) to pharmacotherapy range from <5% to >90%. Negative determinants include multiple daily dosing (MDD), chronic duration, and asymptomatic disease. Reports suggest that once-daily (QD) dosing may improve adherence, but their findings are inconclusive. OBJECTIVE: The purpose of this study was to compare the rates of adherence with QD, twice-daily (BID), and MDD antihypertensive drug regimens. METHODS: MEDLINE, Embase, and International Pharmaceutical Abstracts databases were searched to identify comparative trials of patient adherence to antihypertensive medication in solid, oral formulations. Data were combined using a random-effects meta-analytic model. RESULTS: Eight studies involving a total of 11,485 observations were included (1,830 for QD dosing, 4405 for BID dosing, 4147 for dosing >2 times daily [>BID], and 9655 for MDD), in which the primary objective was to assess adherence. The average adherence rate for QD dosing (91.4%, SD = 2.2%) was significantly higher (Z = 4.46, P < 0.001) than for MDD (83.2%, SD = 3.5%). This rate was also significantly higher (Z = 2.22, P = 0.026) than for BID dosing (92.7% [SD = 2.3%] vs 87.1% [SD = 2.9%]). The difference in adherence rates between BID dosing (90.8%, SD = 4.7%) and >BID dosing (86.3%, SD = 6.7%) was not significant (Z = 1.82, P = 0.069). CONCLUSIONS: The results of this meta-analysis demonstrate that with antihypertensive medications, QD dosing regimens are associated with higher rates of adherence than either BID or MDD regimens.

Initial perceptions of key stakeholders in Ontario regarding independent prescriptive authority for pharmacists.

BACKGROUND: A number of jurisdictions, both in Canada and internationally, have recently expanded pharmacists' scope of practice to allow prescriptive authority. OBJECTIVE: To ascertain the initial perceptions of the Ontario government and health professional stakeholder groups regarding the prospect of prescriptive authority for pharmacists. METHODS: Qualitative research methods were used; data sources were policy documents and semi-structured interviews with key informants from the Ontario government and pharmacy and medical professional organizations. Purposive and snowball sampling strategies were used to identify 17 key informants. Fifty-one relevant policy documents were retrieved through searches of organizational websites and interviewee suggestions. Interview transcripts and documents were content analyzed independently by 2 researchers; and once consensus was achieved on key themes, the primary investigator analyzed the remainder. RESULTS: Pharmacy organizations and Ontario government representatives both expressed support for pharmacist prescriptive authority, suggesting that it would enhance patient access to primary care. Medical organizations were opposed to this expanded pharmacist role, arguing that pharmacists' lack of training and experience in diagnosis and prescribing would endanger patient safety. Other concerns were fragmentation of care and pharmacists' lack of access to patient clinical information. Some government and pharmacy informants felt that pharmacist prescribing would decrease health system costs through substitution of cheaper health professionals for physicians, while others felt that costs would increase due to increased utilization of services. Medical organizations preferred delegated medical authority as the policy alternative to pharmacist prescribing. CONCLUSIONS: Widely different views were expressed by the Ontario government and pharmacy organizations on the one hand and medical professional organizations on the other hand, regarding the potential impact of pharmacist prescribing on patient safety and access to primary care. This is likely due, at least in part, to the lack of evidence on the expected impact of this expanded pharmacist role. More research is needed to help inform discussions regarding this issue.

Development and pilot testing of a multiple mini-interview for admission to a pharmacy degree program.

OBJECTIVES: To develop and pilot test a multiple mini-interview (MMI) to select students for admission to a pharmacy degree program. METHODS: A nominal group process was used to identify 8 important nonacademic attributes of pharmacists, with relative importance determined by means of a paired-comparison survey of pharmacy stakeholders (ie, university-affiliated individuals with a vested interest in the quality of student admitted to the pharmacy program, such as faculty members, students, admissions staff members, and practitioners). A 10-station MMI based on the weighted-attribute blueprint was pilot tested with 30 incoming pharmacy students. MMI score reliability (intraclass correlation coefficient [ICC]) and correlation with other admissions tool scores were determined. RESULTS: Station scores provided by student interviewers were slightly higher than those of faculty member or practitioner interviewers. While most interviewers judged a 6-minute interview as "just right" and an 8-minute interview "a bit long," candidates had the opposite opinion. Station scenarios had face validity for candidates and interviewers. The ICC for the MMI was 0.77 and correlations with prepharmacy average (PPA) and Pharmacy College Admission Test (PCAT) composite were negligible. CONCLUSIONS: MMI feasibility was confirmed, based on the finding that interview scores were reliable and that this admissions tool measures different attributes than do the PCAT and PPA.

Ontario family physician readiness to collaborate with community pharmacists on drug therapy management.

BACKGROUND: Empirical evidence suggests that pharmacist-physician collaboration can improve patients' clinical outcomes; however, such collaboration occurs relatively infrequently in the community setting. There has been little research on physicians' perspectives of such collaboration. OBJECTIVE: To ascertain Ontario family physician readiness to collaborate with community pharmacists on drug therapy management. METHODS: The survey instrument was based on the transtheoretical model of behavior change. It enquired about 3 physician behaviors that represented low-, mid-, and high-level collaboration with pharmacists. The survey was distributed by fax or mail to a random sample of 848 Ontario family physicians and general practitioners, stratified by practice location (urban/rural). RESULTS: The response rate was 36%. Most respondents reported conversing with community pharmacists about a patient's drug therapy management 5 or fewer times per week. Eighty-four percent reported that they regularly took community pharmacists' phone calls, whereas 78% reported that they sometimes sought pharmacists' recommendations regarding their patients' drug therapy. Twenty-eight percent reported that they sometimes referred their patients to community pharmacists for medication reviews, with 44% unaware of such a service. There were no differences in physician readiness to engage in any of the 3 collaborative behaviors in urban versus rural settings. More accurate patient medication lists were perceived as the main advantage (pro) of collaborating with community pharmacists and pharmacists' lack of patient information as the main disadvantage (con). Collectively, perceived pros of collaboration were positive predictors of physician readiness to collaborate on all 3 behaviors, whereas perceived cons were negative predictors for the low- and mid-level behaviors. Female physicians were more likely than males to seek pharmacists' recommendations, whereas more experienced physicians were more likely to refer patients to pharmacists for medication reviews. CONCLUSIONS: Overall, Ontario physicians were more engaged in the low- and mid-level collaboration with community pharmacists with respect to drug therapy management. The strongest predictor of physician readiness to collaborate was perceived advantages of collaboration.

TEACH: Trial of Education And Compliance in Heart dysfunction chronic disease and heart failure (HF) as an increasing problem.

UNLABELLED: In this manuscript we outline the development of a randomized control trial. INTRODUCTION: Heart failure (HF) is one of the leading causes of hospitalization in North America. While great advances have been made in the treatment of this disease, many factors limit the effectiveness of treatment. The objective of this Trial of Education And Compliance in Heart failure patients (TEACH) was to measure in patients with heart failure who were hospitalized and then discharged into the community, the impact of a comprehensive outpatient educational intervention on: 1) a composite endpoint of mortality, readmissions and visits to the emergency room for all causes, 2) the impact of the intervention on health-related quality of life, 3) the impact of the intervention on compliance to medication and 4) the economic impact of providing such an intervention to patients. RESEARCH DESIGN: This was a prospective cluster randomized controlled clinical trial in patients who were admitted to hospital with a diagnosis of heart failure (HF). Patients were stratified by reason for admission to hospital. Stratum 1 included patients whose primary reason for admission was HF and stratum 2 included patients whose primary reason for hospital admission was not HF. HYPOTHESIS: HF patients who receive an enhanced educational intervention from their community pharmacist will 1) have an absolute risk reduction in the number of events of 20%, 2) be more compliant, 3) will demonstrate less health-related quality of life (HRQoL) impairment as measured by disease-specific and generic HRQoL instruments and 4) will lower costs/Quality Adjusted Life Years (QALY) due to fewer total events per patient. OUTCOMES: Outcomes were collected every 3 months from baseline to the end of 1 year. Events were tracked using a comprehensive database that we developed and validated. In order to measure compliance we used electronic measures known as Track Caps (MEMS). We also used pharmacy refill data that was provided to us from all community pharmacies the patient used. This data was analyzed and interpreted using a validated formula developed by Steiner et al. (1996).